In line with previous reports of IL-6 as a biomarker of severe disease5, some studies examining small patient cohorts have suggested treatment with tocilizumab (anti-IL6 receptor) may improve outcomes in severe COVID-19 patients6,7. Here, IL6 is linked to COVID-19.